AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
About this item
Full title
Author / Creator
Antonarakis, Emmanuel S , Lu, Changxue , Wang, Hao , Luber, Brandon , Nakazawa, Mary , Roeser, Jeffrey C , Chen, Yan , Mohammad, Tabrez A , Chen, Yidong , Fedor, Helen L , Lotan, Tamara L , Zheng, Qizhi , De Marzo, Angelo M , Isaacs, John T , Isaacs, William B , Nadal, Rosa , Paller, Channing J , Denmeade, Samuel R , Carducci, Michael A , Eisenberger, Mario A and Luo, Jun
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Enzalutamide and abiraterone target the androgen receptor and androgen synthesis and are used to treat castration-resistant prostate cancer. A splice variant of the androgen receptor is associated with resistance to both drugs.
It is now accepted that castration-resistant prostate cancer is not androgen-independent and continues to rely on andro...
Alternative Titles
Full title
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Authors, Artists and Contributors
Author / Creator
Lu, Changxue
Wang, Hao
Luber, Brandon
Nakazawa, Mary
Roeser, Jeffrey C
Chen, Yan
Mohammad, Tabrez A
Chen, Yidong
Fedor, Helen L
Lotan, Tamara L
Zheng, Qizhi
De Marzo, Angelo M
Isaacs, John T
Isaacs, William B
Nadal, Rosa
Paller, Channing J
Denmeade, Samuel R
Carducci, Michael A
Eisenberger, Mario A
Luo, Jun
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4201502
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4201502
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1315815
